The healthcare industry is abuzz with enthusiasm as GenAI-related news, agreements, and documentation take precedence, aiming to reduce expenses and streamline administrative procedures.
GenAI has potential applications across the pharma sector value chain
GenAI has the potential to revolutionize various aspects of the pharmaceutical industry's value chain. It can expedite the process of drug discovery, improve the efficiency of clinical trials and drug approval, optimize manufacturing and supply chain operations, enhance marketing and sales efforts, and ultimately improve patient outcomes and healthcare delivery. Here are some specific applications of GenAI in the pharmaceutical sector:
Target Identification and Lead Generation & Optimization: GenAI can automate the identification of potential drug targets and optimize lead generation, reducing the time and resources required for drug development.
Preclinical & Clinical Trials: GenAI can enhance clinical trials by facilitating the screening process for eligibility, aiding in participant enrollment, predicting trial outcomes, and optimizing trial design.
Drug Approval: GenAI can assist in the drug approval process by accelerating the identification of potential drug candidates, improving the efficiency of preclinical testing and clinical trial design, and predicting regulatory marketing approval based on trial results.
Manufacturing: GenAI can optimize drug manufacturing processes by predicting quality outcomes, thereby increasing efficiency and reducing costs.
Supply Chain & Distribution: GenAI can optimize the pharmaceutical supply chain and distribution by automating demand prediction, route optimization, and inventory management, leading to greater efficiency and cost reduction.
Marketing & Sales: GenAI can enhance pharmaceutical sales and marketing efforts by automating customer segmentation, predicting trends, and enabling personalized strategies for improved engagement and performance.
End Users: GenAI can improve healthcare delivery by personalizing treatments, predicting patient outcomes, automating health monitoring, and improving patient compliance, resulting in enhanced patient care.
The applications of GenAI in the pharmaceutical industry are vast and have the potential to bring significant advancements to various stages of drug development, manufacturing, supply chain management, marketing, sales, and ultimately, patient care.
Healthcare leaders acknowledge genAI as a catalyst to a paradigm shift
GenAI exhibits immense potential within healthcare
The ability to analyze large amounts of data and generate text, audio, and video content makes genAI an ideal technology for various applications in research and development (R&D) and patient support within the healthcare industry.
R&D Transformation: genAI has the potential to revolutionize pharmaceutical R&D by automating complex processes, predicting drug candidates, and enabling the development of innovative therapies. This can lead to significant advancements in treatment options and ultimately result in improved patient outcomes.
Enhanced Patient Support: genAI can greatly improve patient support by personalizing care plans, offering real-time monitoring and feedback, and providing intelligent virtual assistants. These advancements contribute to better patient engagement, adherence to treatment plans, and overall well-being.
Streamlined Administration: genAI technology has the ability to streamline healthcare operations, administration, and management by automating tasks, optimizing resource allocation, and improving decision-making processes. This results in increased operational efficiency and cost savings.
Advanced Data Analytics: genAI can enhance healthcare data and analytics capabilities by utilizing advanced algorithms to analyze extensive datasets, extract meaningful insights, and enable predictive modeling. These insights can drive data-driven strategies, facilitate precision medicine, and promote evidence-based healthcare practices.
GenAI's capabilities in data analysis and content generation offer immense potential for transforming R&D processes, improving patient support, streamlining administration, and enhancing data analytics within the healthcare industry.
Key use cases of genAI in healthcare
From drug development to patient care, emerging genAI use cases seem to impact every facet of pharma and healthcare.
Drug Development
Adaptyv Bio Develops AI-Powered Protein Engineering Platform
Adaptyv Bio in Switzerland created a genAI-powered platform for protein engineering. It designs and optimizes proteins for pharmaceuticals, biotech, and healthcare.
The protein engineering platform combines genAI algorithms, robotics, microfluidics, and synthetic biology to optimize protein sequences. Using algorithms and machine learning, it creates customized proteins with desired characteristics. It provides tools for designing and optimizing proteins for drug discovery and biotherapeutics. By analyzing protein data, the platform utilizes machine learning to produce unique designs, accelerating breakthrough solutions for researchers.
By leveraging the capabilities of genAI, Adaptyv Bio's protein engineering platform revolutionizes the traditional methods of designing and optimizing proteins. It offers more efficient and effective approaches to protein engineering, surpassing the conventional trial-and-error process. With this platform, researchers can quickly explore a wide range of protein variants with desired properties, speeding up the protein engineering process and facilitating the creation of proteins suitable for diverse industries. This technology empowers scientists to delve into a vast design space, potentially leading to the discovery of novel treatments and therapeutics that can transform the field of healthcare.
NVIDIA Rolls Out GenAI Cloud Services Suite to Advance Drug Discovery
NVIDIA has launched genAI cloud services in its BioNeMo Cloud suite for customizing AI models in genomics, chemistry, biology, and more. BioNeMo accelerates drug discovery pipelines.
BioNeMo includes six optimized models: AlphaFold2, DiffDock, ESMFold, ESM2, MoFlow, and ProtGPT-2. They assist with protein structure determination, molecule docking, protein structure prediction, and more.
The BioNeMo Cloud service offers pre-trained AI models and customization for drug discovery. NVIDIA claims it provides an easy-to-use interface and can be combined with the NVIDIA DGX Cloud for enhanced capabilities. Biotech startups like Evozyne and Insilico Medicine utilize BioNeMo.
Huma.AI Launches GenAI Platform to Accelerate Drug Development
Huma.AI has launched an AI platform for life sciences to speed up medication development. It automates manual data curation through NLP and analyzes unstructured data sources. The platform combines internal and external evidence using generative technology from OpenAI.
The genAI platform helps with clinical development, post-market surveillance, and real-world evidence. It expedites reading and analyzing medical literature and selects relevant articles for post-market surveillance. Huma.AI assists companies in gathering insights and adjusting their products based on feedback.
GenAI is adopted for marketing, customer service, sales, and learning. It enhances conversion rates and revenue. Huma.AI's platform addresses the resource-intensive drug development process and aids decision-making in life sciences.
Absci Develops GenAI-Powered Antibody Design Platform
Absci utilizes genAI to develop innovative antibody-based therapeutics. Their zero-shot genAI antibody design approach creates antibodies that bind to specific targets without relying on training data from existing antibodies. By leveraging AI, they can design custom antibodies in silico before conducting real-world testing, cutting the time for advancing new drug targets to clinical trials from six years to 18-24 months. This accelerates the delivery of life-saving medications, particularly in critical areas like oncology. Absci's AI-designed antibodies show higher clinical success rates and have the potential to revolutionize antibody drug discovery.
Absci's approach improves success rates and reduces the time to reach clinical trials by designing drugs in silico without relying on existing data from antibodies. This zero-shot approach enables the discovery of novel drug targets and the optimization of biotherapeutic candidates. It shortens preclinical development cycles and enhances the success rates of clinical trials. Absci's recent expansion to Zug, Switzerland further strengthens their commitment to innovation in the field.
Sygnature Taps GenAI for Drug Design
Sygnature Discovery has partnered with Iktos, a French AI drug discovery startup, to implement Makya, Iktos' de novo generative design software. Makya enhances Sygnature's drug design capabilities by assisting scientists in designing new compounds and optimizing the drug discovery process.
Makya is a genAI-driven software for multi-parametric optimization (MPO) in drug discovery. It can be accessed as a SaaS platform or installed on the customer's premises. Makya automates the process of designing virtual molecules with desired properties, addressing the challenge of identifying compounds that meet multiple parameters for disease treatment.
By integrating Makya, Sygnature aims to offer efficient and innovative drug discovery solutions to its global customers. The technology generates high-quality compound ideas and enables rapid updates to quantitative structure-activity relationship (QSAR) models. Through the combination of medicinal and computational chemistry with AI/ML technologies, Sygnature enhances compound design capabilities, reducing costs and timelines in lead optimization projects.
Imaging & Diagnostics
Google Develops Medical LLM for Image Analysis
Google has developed Med-PaLM 2, a medical large language model (LLM) that can analyze images and answer medical questions. Med-PaLM 2 is designed to review X-rays and mammograms, generate reports, and engage in follow-up dialogue. This advancement contributes to the growing interest in using genAI for medical applications.
Med-PaLM 2 achieved an 85% accuracy rate on questions related to the US Medical Licensing Exam. Unlike other systems, it allows doctors to engage in conversations and simulate discussions with the LLM, making AI image analysis more transparent and interactive. Google has also incorporated multi-modality, enabling Med-PaLM 2 to synthesize and communicate information from medical images using its PaLM-E model.
By combining image analysis and question-answering capabilities, Med-PaLM 2 represents a significant advancement in AI healthcare applications. It empowers physicians by enabling them to question and engage with the conclusions provided by the LLM. This tool has the potential to break down information barriers and provide quick and accurate access to medical data for critical tasks such as diagnostics, research, and patient care.
PathAI Advances Anatomic Pathology with GenAI
PathAI has launched the digital pathology platform AISight and AIM-PD-L1 NSCLC RUO algorithm under its Early Access Program. AISight is a web-based platform for AI-driven research in pathology, enabling the management and analysis of whole slide images. AIM PD-L1-NSCLC is an AI algorithm system designed to predict the tumor proportion score (TPS) in non-small cell lung cancer (NSCLC) samples, providing precise assessment of PD-L1 expression across multiple stains.
PathAI utilizes genAI algorithms to improve accuracy and productivity in digital pathology. However, AISight and the AIM-PD-L1 RUO NSCLC algorithms are for research use only. The platform and algorithm are being implemented in 13 prominent US institutions as part of the Early Access Program. PathAI recently raised $165 million in Series C financing and plans to collaborate with pharmaceutical and diagnostic partners to enhance patient outcomes using AI-powered technology.Glass
Health Implements GenAI to Optimize Clinical Diagnosis
San Francisco-based Glass Health has released Glass AI, a technology that uses a large language model (LLM) to produce treatment plans or diagnoses based on patient symptoms. It aims to improve accuracy in diagnoses and clinical strategies.
Glass AI assists healthcare professionals in creating a differential diagnosis and formulating a clinical plan. It provides suggestions for early detection, diagnosis, and disease management, helping doctors gain medical knowledge quickly and improve patient care.
GenAI has the potential to revolutionize healthcare by enabling faster and precise diagnoses. It analyzes structured and unstructured data to offer personalized care, supporting tailored interventions and gaining new disease insights. Glass Health employs genAI to produce diagnoses or clinical plans based on symptoms.
Glass Health launched its platform in March 2022 and secured funding from Breyer Capital and Y Combinator. The company aims to use the funding to accelerate the development and delivery of patient care tools.
HMS Unveils Synthetic Image Generation Algorithm
Harvard Medical School (HMS) researchers have developed LF-SynthSR, an ML super-resolution algorithm that generates high-resolution synthetic images from low-resolution brain MRI scans. This enables the study of rare illnesses and underrepresented populations in neuroimaging research.
LF-SynthSR is a CNN algorithm that converts low-field-strength T1- and T2-weighted brain MRI sequences into high-resolution images resembling T1-weighted MP-RAGE acquisition. It is trained on synthetic input images and can generate 1mm isotropic synthetic images from low-field strength MRIs using voxels 10 times smaller than the original data.
LF-SynthSR allows automated 3D analysis of clinical scans using portable, low-field MRI scanners. The algorithm successfully generates synthetic MP-RAGE images, and evaluations show correlated regions-of-interest volumes. This technology improves portable MRI image quality and facilitates neuroimaging research for rare disorders and underrepresented populations.
Precision Medicine
Tempus Unveils GenAI-Enabled Tool for Precision Medicine
US-based company Tempus has launched Tempus One, an AI-enabled clinical assistant that provides clinicians with immediate access to a patient's complete clinical and molecular profile. It leverages genAI and is available through the Tempus Hub desktop and mobile app, offering real-time clinical decision support.
Tempus One is a voice and text assistant that simplifies access to patient information for healthcare providers. It provides instant access to clinical and molecular profiles and additional datasets. Clinicians can access test reports, receive status updates, filter patient data, review actionable biomarkers, and query clinical guidelines. It integrates into clinical care settings and is accessible through desktop and mobile apps. It has been developed based on user feedback to meet physicians' needs.
Tempus One simplifies genomic testing in clinical settings, providing clinicians with efficient access to patient data. It facilitates data-driven treatment decisions and brings the power of AI to clinicians' fingertips. This technology has the potential to advance precision medicine and improve patient outcomes. Ongoing user feedback and advancements in genAI are likely to drive further improvements.
Google Launches AI Solutions for Precision Medicine
Google Cloud introduces AI solutions, the Target and Lead Identification Suite, and the Multiomics Suite, for the life sciences sector. These aim to accelerate drug discovery and advance precision medicine. Target and Lead Identification Suite uses AlphaFold and Vertex AI to identify protein targets, while the Multiomics Suite employs GWAS pipelines, Batch API, and Compute Engine for analysis.
Target and Lead Identification Suite enhances in silico drug design by identifying amino acid functions and predicting protein structures. It supports drug discovery pipelines, reducing failures with Vertex AI and AlphaFold. Multiomics Suite interprets genomic data, streamlining precision medicine, and reducing time and costs associated with data.
Google Cloud's AI solutions can expedite cancer treatments and medications, benefiting patients. They streamline processes, accelerate drug development, with notable adopters like Pfizer. The Target and Lead Identification Suite predicts antibody structures, facilitates lead optimization for further studies.
Predictive Analytics
NYU Grossman School of Medicine Develops AI-Driven Doctor Assistant
NYU Grossman School of Medicine has developed genAI-powered clinical assistant NYUTron. It analyzes physicians' notes to assess patients' risk of death, length of hospital stay using LLMs. NYUTron eliminates data reformatting from EHR for meaningful insights.
NYUTron is a breakthrough in healthcare prediction models, leveraging LLMs. It accurately analyzes clinical notes, surpasses traditional models, and demonstrates 80% accuracy in predicting readmissions. Real-time alerts enable prompt action, improving workflow efficiency and increasing patient interaction time.
LLMs in healthcare have immense potential for guiding physicians and improving patient care. NYUTron showcases LLM capabilities in supporting providers with predictive models. Future applications may include billing codes, infection risk prediction, and medication order optimization. NYUTron is being implemented in NYU Langone Health hospitals to predict readmission within a month. It supports healthcare providers as a complementary tool, not a replacement.
Clarify Health Unveils GenAI Copilot for Predictive Analytics
California-based startup Clarify Health Solutions unveils genAI copilot named Clara, based on the Clarify Atlas platform. Clara leverages comprehensive data to model individual patients' future health status, providing predictions on disease progression and treatment responses.
Clara utilizes machine learning algorithms trained on vast amounts of claims, clinical, and social determinant data. It simulates potential health trajectories for patients and enables what-if scenarios to identify optimal care paths. By predicting future health outcomes, Clara equips providers and payers with data-driven insights for proactive and personalized care.
Clarify Health aims to empower healthcare organizations with Clara to reduce costs, improve efficiency, and enhance patient outcomes. With $150 million in funding, the startup plans to strengthen clinical informatics capabilities and value-based payments technology. Clara's transformative potential lies in offering tailored capabilities to shape healthcare delivery according to unique needs.
Pieces Offers AI-Generated Insights for Care Teams
Pieces Technologies introduces Pieces Predict, an AI-driven healthcare data analytics software for care teams. It provides AI-generated patient summaries and insights within the electronic health record (EHR), reducing manual efforts and improving efficiency. This streamlined approach helps cut costs and enhances workflow in healthcare settings.
Pieces Predict utilizes natural language processing (NLP) technology to extract key information from EHR notes, identifying at-risk patients and considering social determinants of health (SDoH). It continuously monitors patient data within the EHR, detecting changes and suggesting necessary interventions. The integration of SDoH data improves recommendations and predictions.
With labor shortages and limited resources in healthcare, Pieces leverages AI to support physicians, nurses, and case managers. Pieces Predict enables early interventions by providing automated insights and predictions. Within the Epic platform, it offers clinical summaries, projected discharge dates, and identification of discharge barriers. This integration facilitates efficient decision-making and proactive interventions for better patient care.
Synthetic Data
Segmed Offers Synthetic Medical Imaging Data
Medical data startup Segmed partners with NVIDIA and RadImageNet to produce synthetic medical imaging data for research and development. Synthetic data of CT, MRI, ultrasound, and endoscopic surgery will train and augment downstream AI models.
Generative imaging models create synthetic images and segmentations closely resembling real-world data. This collaboration expands training data availability and enhances patient datasets. Synthetic data applications include modality classification and protecting patient privacy.
Synthetic data enhances research datasets and improves AI algorithms and models. Segmed's self-serve platform, Segmed Insight, provides access to synthetic and de-identified real-world imaging records. The seed funding of $5.2 million will strengthen the platform and expand the customer base.
NVIDIA Launches GenAI-Powered Tool for Radiology
NVIDIA's RadImageGAN uses genAI to generate realistic medical images by combining CT, MRI, and ultrasound data. This extensive dataset closely resembles real scans, providing a virtually infinite supply for studying different imaging modalities. With 165 classes across 14 anatomical regions, RadImageGAN applies StyleGAN-XL and was trained on 1.3 million RadImageNet images.
RadImageGAN revolutionizes medical imaging, offering an extensive dataset for research, education, and training. It enables exploration of various imaging modalities beyond limited real-world data. It aids in developing and validating new imaging techniques and algorithms, improving diagnostics and patient outcomes. Synthetic medical images empower radiologists to enhance their skills and contribute to advancements in medical imaging technology.
Syntegra Develops AI-Based Tool for Synthetic Healthcare Data Generation
California startup Syntegra introduces Syntegra Medical Mind 2.0, a synthetic data engine that generates realistic patient data for healthcare applications while preserving privacy.
Syntegra uses genAI algorithms to create statistically equivalent synthetic patient datasets without real patient information. This maintains data complexity and heterogeneity, making it valuable for disease modeling, AI training, clinical trials, and healthcare analytics. The platform has been trained on datasets with over 20 million patient records and supports different healthcare data models.
Syntegra's synthetic data technology improves decision-making, leading to accurate diagnoses, personalized treatments, and better patient outcomes. It has the potential to enhance healthcare processes, resource allocation, and patient care. AI in healthcare can transform precision medicine, clinical research, and population health management.
Elevance Health Develops Synthetic Data Platform
American health insurance provider Elevance Health partners with Google Cloud to develop a synthetic data platform for training AI algorithms to detect false claims and anomalies in patients' health, while safeguarding personal information.
Elevance Health generates 1.5 to 2 petabytes of synthetic data, including medical histories and healthcare claims, using algorithms and statistical models. This approach validates and trains AI systems while addressing privacy concerns. It has already used AI algorithms to detect insurance fraud and aims to expand these capabilities. The platform will also personalize care for members by identifying the need for medical intervention.
Synthetic data is crucial for accurate ML models, providing access to large, labeled datasets. It has gained traction in various industries, such as robotics and autonomous vehicles. Elevance Health and Google Cloud aim to bring synthetic data applications to the healthcare sector, enhancing care and fraud detection.
Document Automation
DiagnaMed Automates Healthcare Forms with GenAI
Canadian startup DiagnaMed launches FormGPT.io, a genAI data collection and analysis solution powered by GPT-4. It enables healthcare providers and researchers to create customized forms and surveys for patient data collection, feedback, and treatment. The platform improves data accuracy and relevance, allowing for more informed decisions and better patient outcomes.
FormGPT.io is based on DiagnaMed's CERVAI genAI brain health platform. It utilizes GPT-4 to create tailored forms and surveys, enhancing user services, workflow, patient outcomes, and engagement. It supports healthcare providers and researchers in monitoring patient progress and analyzing results.
Automation is increasingly used in healthcare, and genAI technologies like FormGPT.io streamline operations and improve care quality. The solution enhances workflow, patient outcomes, and efficiency, making it a valuable tool for healthcare providers and researchers. DiagnaMed's partnership with the University of Kansas for VR and AI neurodiagnostic systems demonstrates their commitment to innovation in healthcare.
WELL Health Introduces GenAI-Powered Medical Transcription Tool
Canadian company WELL Health introduces WELL AI Voice, an ambient AI scribe that automates documentation tasks for physicians. It uses genAI capabilities to centralize attention on patient needs, reduce admin burdens, and enhance care.
WELL AI Voice transcribes patient-physician interactions in real-time, eliminating manual data entry for physicians. It leverages ambient AI, NLP, and generative speech recognition algorithms to accurately capture dialogue. It seamlessly integrates with EHR systems like OSCAR Pro and WELL's Profile and Cerebrum EMRs.
The platform improves productivity and patient engagement by automating documentation. It has the potential to transform healthcare by allowing physicians to spend more time on direct patient care. Future enhancements may include expanded language support and improved transcription accuracy. It could also benefit other healthcare professionals and improve overall system efficiency and patient outcomes.
3M HIS Advances Clinical Documentation with GenAI
3M Health Information Systems (HIS) and Amazon Web Services (AWS) collaborate to enhance 3M M*Modal ambient intelligence solutions. AWS's ML and genAI services will streamline the deployment of 3M HIS' clinical documentation and virtual assistant solutions. This collaboration aims to reduce administrative burdens on physicians and improve the patient-physician experience.
The collaboration improves 3M HIS's conversational AI platform, supporting cloud-based solutions like 3M MModal Fluency Direct for real-time speech recognition in electronic health records (EHRs) and 3M MModal Fluency Align for ambient clinical documentation. 3M HIS aims to develop ML-based solutions that integrate seamlessly into workflows and give physicians control over patient health record information. The partnership enhances the effectiveness of 3M's ambient clinical documentation solutions, providing support for documenting patient interactions while ensuring compliance.
The collaboration between 3M HIS and AWS advances clinical documentation, automates tasks, and increases healthcare efficiency. It improves patient outcomes and satisfaction by enabling effective communication between providers and patients. By leveraging AWS technologies like Amazon Bedrock, 3M HIS expands its conversational AI capabilities and offers usability to physicians. The collaboration also supports affordable, secure, and accurate notetaking and documentation for clinical staff, ultimately enhancing patient care delivery and the healthcare experience.
Microsoft Launches AI-Automated Clinical Documentation Solution
Microsoft collaborates with Nuance to launch Dragon Ambient eXperience (DAX) Express, an automated clinical documentation application. DAX Express generates draft clinical notes, enabling quick review and completion during patient visits or telehealth discussions.
DAX Express utilizes OpenAI's GPT-4 to integrate conversational AI, ambient, and genAI technologies, providing trustworthy and secure AI products compliant with HIPAA regulations.
The collaboration aims to support digitalization in healthcare and provide AI-powered solutions for healthcare professionals. DAX Express is offered to existing users of DAX ambient one and Dragon Medical One, enabling a seamless transition and maximizing investments in Nuance solutions. Clinicians can benefit from intuitive features and reduced cognitive burdens, contributing to a more enjoyable medical practice.
Patient Care Management
Solutionreach Adds GenAI Capabilities for Patient Review Management
Solutionreach enhances its patient engagement platform by integrating genAI tools for online review management. This integration enables faster responses to online reviews while maintaining a personalized approach, empowering practices to manage their online brand reputation effectively.
Through genAI, Solutionreach customers can generate intelligent responses, monitor brand sentiment, and analyze patient feedback accurately. Summaries and sentiment analysis of patient reviews help identify trends and address concerns, improving patient satisfaction and loyalty.
The rise of online platforms allows patients to share healthcare experiences widely. GenAI models, like NLP and deep learning, analyze patient reviews efficiently, providing valuable insights and reducing the burden on healthcare professionals. Solutionreach's technology enables a proactive approach to shaping brand narrative, building patient relationships, and supporting sustainable growth.
DiagnaMed Rolls Out GenAI-Powered Patient Care Management Solution
Canadian startup DiagnaMed launches PalGPT.ai, a genAI solution that facilitates human-like conversations and provides a platform for users to share their thoughts.
PalGPT.ai is integrated into DiagnaMed's CERVAI brain health platform, offering solutions for improving brain health. It provides a private space for users to share and learn, offering practical advice, self-improvement tips, and emotional support.
The AI companion, PalGPT.ai, contributes to the healthcare industry's transformation, complementing traditional medical interventions. However, it has limitations and should not be relied upon for serious medical issues. Consulting a healthcare professional is recommended.
DiagnaMed aims to overcome challenges and contribute to the growth of genAI in healthcare. PalGPT.ai is the second commercial product from their Health GenAI division, focusing on enhancing patient outcomes and operational efficiency.
Skyscape Integrates AI Capabilities with Digital Healthcare Platform
Skyscape integrates genAI capabilities with its digital healthcare platform, enabling personalized and efficient communication between healthcare providers and patients. The AI features leverage NLP to interpret patient communications, reducing workload and improving information accessibility. The platform incorporates ML algorithms to learn and improve over time.
Skyscape's AI capabilities alleviate healthcare providers' workload and enhance patient communication in the platform. By delivering precise and timely information, it contributes to improving patient outcomes. There is potential for integration into other healthcare systems, further enhancing patient care and communication.
Workforce Management
UNC Health Streamlines Workforce Using GenAI
UNC Health partners with Microsoft to implement Azure OpenAI Service and develop a genAI-powered internal chatbot. This chatbot aims to streamline administrative processes in healthcare and improve the patient-focused experience.
The disruption lies in UNC Health's utilization of AI to streamline administrative tasks for healthcare professionals. The genAI chatbot allows quick access to necessary reference materials, reducing the burden of administrative duties and enabling more time for patient care.
UNC Health is an early adopter of genAI in healthcare, employing Microsoft's Azure-powered tools. The phased rollout of the chatbot will start with a small group of clinicians and administrators, with plans for later expansion.
By partnering with Microsoft, UNC Health aims to optimize work processes and protect information. The introduction of the chatbot represents the initial step in leveraging AI technology for transforming healthcare operations, with potential for discovering additional use cases.
UNC Health's collaboration with Microsoft aims to enhance healthcare delivery in North Carolina and beyond. The responsible and safe application of technologies like Azure OpenAI Service is geared towards improving the health and well-being of individuals served by UNC Health.
IKS Health Implements GenAI to Manage Health Staff Workload
The partnership between IKS Health and Abridge aims to develop AI-based technology to alleviate administrative burdens on healthcare providers. Abridge's genAI solution will streamline IKS's clinical documentation services, while IKS will provide valuable feedback to advance Abridge's AI technologies.
Utilizing Abridge's genAI, IKS aims to automate clinical note drafting and structured data creation, improving care delivery workflows and reducing provider burnout. The integration of AI holds promise for increased efficiency and improved clinical outcomes.
The partnership addresses administrative burdens, burnout, and workforce shortages in healthcare. By integrating genAI, IKS empowers clinicians to deliver better and safer care. Both companies prioritize data privacy and adhere to responsible AI principles.
IKS Health has invested in Abridge, and Abridge has raised funds to enhance its platform. These investments will support the development of AI technologies, facilitating the creation of notes from conversations.
Health Informatics
Epic Integrates Microsoft's GenAI into EHRs
US-based Epic Systems and Microsoft partner to integrate Microsoft's OpenAI Azure Services. The goal is to use genAI to support healthcare providers in minimizing tasks and prioritizing care.
Microsoft's genAI analyzes EHR data, identifying patterns and relationships. It incorporates natural language processing to interpret unstructured data, empowering it to extract relevant information. The integration streamlines documentation tasks.
The integration of Epic's EHR system with Microsoft's genAI aims to improve decision-making, operational efficiency, and personalized care. UC San Diego Health, UW Health, and Stanford Health Care are early adopters using genAI-infused EHR.
Carbon Health Introduces GPT-4 Charting for EHR
Carbon Health developed an AI tool that generates medical records from physician-patient conversations. Recorded meetings are transcribed using Amazon's AWS Transcribe Medical.
An ML model uses the transcript, medical records, and test results to generate summarized notes. The software, called "Carby," integrates with EHR systems and leverages OpenAI's GPT-4.
Carbon Health's EHR system notifies providers to review and validate the generated summaries. The company claims that 88% of the AI-generated content is accurate. Carbon Health secured $100 million in funding, enabling expansion and technological advancements.
Trials Optimization
Massive Bio Launches GPT-4 AI Chatbots for Oncology Trials
Massive Bio introduces a ChatGPT-powered chatbot platform, featuring AskFiona AI and DrArturo AI personas. It revolutionizes access to clinical trial information for cancer patients, referring physicians, and investigators.
AskFiona AI guides cancer patients exploring clinical trials, clarifying processes and evaluating eligibility. DrArturo AI provides personalized details about trials for healthcare providers, offering insights and facilitating communication. The platform streamlines the trial process, improving outcomes and collaboration.
GenAI-powered chatbots enhance participant experience, data collection, and trial processes. Massive Bio aims to advance cancer care and promote patient-provider engagement. The startup empowers patients, reduces hospital-centric systems, and fosters global oncological research.
Massive Bio's funding round supports global expansion, marketing efforts, and innovative oncology clinical trial products. The company unveiled the chatbot platform at ASCO conference, showcasing its commitment to AI-driven solutions.
Quralis Taps GenAI to Accelerate ALS Clinical Trial
US-based biotech company Quralis collaborates with AI startup Unlearn.AI to optimize ALS clinical trials. Unlearn.AI's genAI technology creates digital twins of patients using ML algorithms. These twins simulate the patient's journey if they received a placebo, reducing the control group size and expediting trials.
Digital twins, or synthetic patients, revolutionize clinical trials by serving as an "intelligent control arm." This approach accelerates trials and minimizes exposure to ineffective treatments. It has significant implications for ALS trials, where time is critical for patients.
The partnership between Quralis and Unlearn.AI advances clinical trial design and the use of genAI. Regulatory approvals could expand its use, accelerating drug discovery and improving patient outcomes. Initial focus is on an ALS trial, with potential for wider adoption in other medical conditions.
Surgical Robots
Chinese Academy of Sciences Deploys GenAI for 3D Brain Reconstruction
Quralis and Unlearn.AI collaborate to accelerate ALS clinical trials using genAI technologies. Unlearn.AI creates digital twins of patients using ML algorithms, revolutionizing clinical trial methodology.
Digital twins, or synthetic versions of patients, replicate their clinical journey if they received a placebo. This "intelligent control arm" reduces the control group size, expediting trials and minimizing exposure to ineffective treatments. This innovative method transforms ALS clinical trials and improves patient outcomes.
Quralis and Unlearn.AI's partnership advances clinical trial design. genAI has the potential to revolutionize healthcare, offering an efficient and ethical approach to testing new treatments. Regulatory approvals could expand the use of genAI, accelerating drug discovery.
Initial focus is on ALS trials as a testing ground for the technology. Success could lead to wider adoption across medical conditions, enhancing the efficiency of clinical trials. This collaboration demonstrates the potential for genAI to shape the future of healthcare.
Hebei University Designs GAN-Based Surgical Tool
Hebei University of Technology introduces Surgical GAN, a genAI-based tool for real-time guide wire path planning in vascular interventional surgery (VIS). It utilizes CNN and LSTM networks to enhance path planning for flexible surgical instruments.
Surgical GAN combines CNN and LSTM to extract spatial and temporal features for path planning. By inputting surgical state information, it continuously outputs guide wire tip paths. Training with a dataset of ten surgeons, the tool automates and improves path planning accuracy in real time.
Surgical GAN improves path planning precision compared to baseline networks. This advancement enhances surgical outcomes and patient safety. It can also act as a training tool for novice surgeons or integrate into robotic VIS systems. The technology revolutionizes VIS, making it more precise, efficient, and accessible.
Others
Illumina Launches AI-Powered Genomic Analysis Tool for Disease Prediction
Illumina introduces PrimateAI-3D, an AI algorithm trained on nonhuman primate genomic data for accurate disease prediction. The algorithm utilizes deep neural networks and addresses unknown genetic variants, advancing personalized genomic medicine.
Google Cloud Leverages GenAI to Enhance Clinical Workflows
Use Case: Models
Google Cloud partners with Mayo Clinic to develop AI models for medical research and patient care. The GenAI-powered Enterprise Search enables custom chatbots and semantic search applications, improving diagnoses and research insights.
SimConverse Develops GenAI-Powered User Simulation Platform
Use Case: Patient Simulation
SimConverse develops a genAI-powered simulation platform for healthcare communications training. It emphasizes verbal and non-verbal communication skills, providing customized training and personalized feedback to enhance learning outcomes.
These innovations in genAI technology have the potential to revolutionize healthcare. They enhance disease prediction, precision medicine, diagnostic accuracy, research capabilities, and communication skills for healthcare professionals. These advancements contribute to improved patient outcomes, faster diagnoses, and more effective care delivery.
GenAI integrations to permeate across the pharma value chain
GenAI has the potential to completely transform the healthcare industry by automating critical processes such as drug development, clinical trials, drug approval, manufacturing optimization, supply chain modeling, pharma marketing automation, and personalized treatment plans. By utilizing genAI technology, healthcare can witness significant advancements in these areas, leading to improved efficiency, accuracy, and patient care.
Patents landscape in genAI healthcare
Keep reading with a 7-day free trial
Subscribe to Curious Compass to keep reading this post and get 7 days of free access to the full post archives.